PH94B
Phase 3- Indications
- Social anxiety disorder, Adjustment disorder with anxiety
Company intelligence / Profile preview
Pherin Pharmaceuticals
Los Altos, California, United Statesseamless.ai ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Pherin Pharmaceuticals developed a pipeline of proprietary intranasal small-molecule drugs called pherines for acute treatment of neuropsychiatric and neuroendocrine conditions. Its lead asset, PH94B, reached Phase III trials for social anxiety disorder but had mixed results; PH10 was in clinical development for major depressive disorder. Other assets included PH15 for cognition improvement, PH80 for migraine/hot flashes, and PH284 for appetite-related disorders/cancer cachexia. In early studies—including an exploratory Phase IIa trial—PH284 showed promise in improving hunger in cancer patients with good tolerability. The company was acquired by Vistagen Therapeutics in February 2023 to consolidate the pherine portfolio under one roof.
- Therapeutic areas
- Women's HealthOncologyPsychiatryNeurology
- Modalities
- Small molecules (specifically "pherines," a proprietary class of neuroactive steroids administered intranasally)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Licensed key assets then acquired by Vistagen
Beyond the preview
Go deeper on Pherin Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pherin Pharmaceuticals.